Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Hassan R, et al. Among authors: verschraegen c. Ann Oncol. 2006 Nov;17(11):1615-9. doi: 10.1093/annonc/mdl060. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600983 Free article.
Epidermal growth factor receptor as a biomarker for cervical cancer.
Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Soonthornthum T, et al. Among authors: verschraegen c. Ann Oncol. 2011 Oct;22(10):2166-78. doi: 10.1093/annonc/mdq723. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325449 Free article. Review.
Intracavitary therapies for mesothelioma.
Verschraegen CF. Verschraegen CF. Curr Treat Options Oncol. 2001 Oct;2(5):385-94. doi: 10.1007/s11864-001-0043-3. Curr Treat Options Oncol. 2001. PMID: 12057101 Review.
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. O'Day SJ, et al. Among authors: verschraegen c. Ann Oncol. 2010 Aug;21(8):1712-1717. doi: 10.1093/annonc/mdq013. Epub 2010 Feb 10. Ann Oncol. 2010. PMID: 20147741 Free article. Clinical Trial.
Medical management of colorectal carcinomas.
Verschraegen CF, Pazdur R. Verschraegen CF, et al. Tumori. 1994 Feb 28;80(1):1-11. doi: 10.1177/030089169408000101. Tumori. 1994. PMID: 8191590 Review.
Subacute encephalopathic toxicity of cisplatin.
Verschraegen C, Conrad CA, Hong WK. Verschraegen C, et al. Lung Cancer. 1995 Dec;13(3):305-9. doi: 10.1016/0169-5002(95)00503-x. Lung Cancer. 1995. PMID: 8719070 Review.
ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF, Glover K. Verschraegen CF, et al. Curr Opin Investig Drugs. 2001 Nov;2(11):1631-8. Curr Opin Investig Drugs. 2001. PMID: 11763168 Review.
Frontiers of Ovarian Cancer Therapy.
Balat O, Mohammed E, Kudelka AP, Verschraegen CF, Kavanagh JJ. Balat O, et al. Cancer Control. 1996 Mar;3(2):137-144. doi: 10.1177/107327489600300206. Cancer Control. 1996. PMID: 10792874 Free article.
215 results